National Vision (EYE)
(Delayed Data from NSDQ)
$10.04 USD
+0.07 (0.70%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $10.02 -0.02 (-0.20%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.04 USD
+0.07 (0.70%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $10.02 -0.02 (-0.20%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Zacks News
Innovation Aids Genomic Health, Merger Procedure on Track
by Zacks Equity Research
Genomic Health (GHDX) is on course to realize its impending merger with cancer diagnostics major Exact Sciences, which will integrate brands like Cologuard and OncotypeDX.
Insulet (PODD) Scales 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Insulet (PODD) has various favorable factors to maintain the current high.
National Vision's Store Launches on Track Despite Cost Woes
by Zacks Equity Research
National Vision (EYE) adopts a formula-based approach to open around 75 stores in 2019.
Neogen Gets AOAC Validation for NeoSeek to Ensure Food Safety
by Zacks Equity Research
Neogen's (NEOG) proprietary testing platform gets upgraded to reduce the incidence of bacterial contamination in livestock.
NuVasive's New TLIF Implant Broadens Spine Surgery Option
by Zacks Equity Research
NuVasive's (NUVA) Modulus TLIF-A is designed to work smoothly with the existing MAS TLIF and MAS Midline access systems.
EYE vs. HAE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EYE vs. HAE: Which Stock Is the Better Value Option?
Boston Scientific's (BSX) Vercise Gevia DBS Gets FDA Nod
by Zacks Equity Research
Boston Scientific's (BSX) Vercise Gevia DBS system should boost neuromodulation revenues for the company.
Baxter (BAX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Baxter (BAX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
National Vision (EYE) Q2 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
National Vision's (EYE) Military brand registers robust growth while other brands fail to impress.
National Vision (EYE) Q2 Earnings Miss Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of -4.76% and 1.99%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) Q2 Earnings Preview: What's in the Cards?
by Zacks Equity Research
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is National Vision (EYE) Down 4.7% Since Last Earnings Report?
by Zacks Equity Research
National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
National Vision's (EYE) Q1 Earnings Beat, Margins Decline
by Zacks Equity Research
National Vision's (EYE) consistent strength in comps is owing to higher customer transaction for the past 69 straight quarters.
National Vision (EYE) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 3.13% and 1.34%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: National Vision (EYE) Q1 Earnings Expected to Decline
by Zacks Equity Research
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is National Vision (EYE) Down 7% Since Last Earnings Report?
by Zacks Equity Research
National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
National Vision (EYE) Rides on Positive Comps Amid Cost Woes
by Zacks Equity Research
National Vision (EYE) has been witnessing positive comps owing to increased customer transaction over the last 68 sequential quarters.
Cooper Companies' (COO) CooperVision Gains Momentum Globally
by Zacks Equity Research
Cooper Companies (COO) maintains its leading position in the markets of specialty lenses, supported by highly exclusive products like Biofinity and Clariti.
National Vision (EYE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
National Vision (EYE) Q3 Earnings Match Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 0.00% and 2.72%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
National Vision (EYE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat in Store for Humana (HUM) Stock in Q3 Earnings?
by Zacks Equity Research
Humana's (HUM) Q3 is likely to gain from solid segmental performances and higher enrollment.
Can Molecular Diagnostics Drive Myriad's (MYGN) Q4 Earnings?
by Zacks Equity Research
Myriad (MYGN) likely to deliver solid Q4 results on the diversified Molecular Diagnostics portfolio with products like GeneSight, EndoPredict, BRACAnalysis CDx and Prolaris tests.
What's in Store for Penumbra (PEN) This Earnings Season?
by Zacks Equity Research
Penumbra (PEN) deepens focus on driving innovation, ramping up production and expanding geographies.
Can Dental Growth Drive Henry Schein's (HSIC) Q2 Earnings?
by Zacks Equity Research
Henry Schein (HSIC) is strongly placed to gain from the ongoing trend of digitalization in the global dental market.